Skip to main content
Figure 4 | BMC Cancer

Figure 4

From: Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease – a combined tissue microarray, in vitro and in vivo study

Figure 4

Analysis of mTOR related protein expression in HL. a. Hodgkin-lymphomas with no Rictor overexpression. Rictor and Raptor expression in HRS cells is similar to reactive lymphocytes (0/1+). Rictor expression is 0/1+ in the majority of HL cases (a representative example is shown); Rictor expression was high only in one HL sample (also shown here; arrows indicate tumor cells). Breast cancer cells show Rictor overexpression (2+/3+). (IHC, 200X, 400X). b. NF-kappaB-p50 and Bcl-xL expression may corralete to mTOR activity in HLs based on several IHC stainings; however, this tendency did not reach statistical significance (see results). (Representative IHC stainings are shown in cases with high and low mTOR activity; 400X).

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us